Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 298795, 7 pages
http://dx.doi.org/10.1155/2014/298795
Research Article

High Nuclear Expression of HDGF Correlates with Disease Progression and Poor Prognosis in Human Endometrial Carcinoma

1Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China
2Cancer Research Institute, Southern Medical University, Guangzhou 510515, China
3Department of Pathology, Third Affiliated Hospital of Guangzhou Medical College, Guangzhou 510150, China

Received 21 September 2013; Revised 11 December 2013; Accepted 6 January 2014; Published 17 February 2014

Academic Editor: Chao Hung Hung

Copyright © 2014 Lijing Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. W. Carlson and G. L. Mutter, “Endometrial intraepithelial neoplasia is associated with polyps and frequently has metaplastic change,” Histopathology, vol. 53, no. 3, pp. 325–332, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA. Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Jemal, R. C. Tiwari, T. Murray et al., “Cancer statistics,” CA. Cancer Journal for Clinicians, vol. 54, no. 1, pp. 8–29, 2004. View at Google Scholar · View at Scopus
  4. F. Yu, Q. P. Jiang, Y. Zhou et al., “Abnormal expression of matrix metalloproteinase-9 (MMP9) correlates with clinical course in Chinese patients with endometrial cancer,” Disease Marker, vol. 32, pp. 321–327, 2012. View at Google Scholar
  5. H. Nakamura, Y. Izumoto, H. Kambe et al., “Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein,” The Journal of Biological Chemistry, vol. 269, no. 40, pp. 25143–25149, 1994. View at Google Scholar · View at Scopus
  6. A. D. Everett and J. Bushweleer, “Hepatoma derived growth factor is a nuclear targeted mitogen,” Current Drug Targets, vol. 4, no. 5, pp. 367–371, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Yoshida, H. Nakamura, Y. Okuda et al., “Expression of hepatoma-derived growth factor in hepatocarci-nogenesis,” Journal of Gastroenterology and Hepatology, vol. 18, pp. 1293–1301, 2003. View at Google Scholar
  8. T. H. Hu, C. C. Huang, L. F. Liu et al., “Expression of hepatoma-derived growth factor in hepat ocellular carcinoma,” Cancer, vol. 98, pp. 1444–1456, 2003. View at Google Scholar
  9. J. Huang, C. Chao, T. Su et al., “Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma,” Biochemical and Biophysical Research Communications, vol. 315, no. 4, pp. 950–958, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Ren, X. Tang, J. J. Lee et al., “Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 22, no. 16, pp. 3230–3237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Bernard, E. Litman, J. L. Fitzpatrick et al., “Functional proteomic analysis of melanoma progression,” Cancer Research, vol. 63, no. 20, pp. 6716–6725, 2003. View at Google Scholar · View at Scopus
  12. S. Wang and W. Fang, “Increased expression of hepatoma-derived growth factor correlates with poor prognosis in human nasopharyngeal carcinoma,” Histopathology, vol. 58, no. 2, pp. 217–224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. E. E. Ioachim, A. C. Goussia, E. G. Kitsiou, K. Charalabopoulos, E. Mermiga, and S. Stefanaki, “Immunohistochemical expression of retinoblastoma gene product in normal, hyperplastic and malignant endometrium. Correlation with p53 protein expression, c-erbB-2, hormone receptors' status and proliferative activity,” Disease Markers, vol. 18, no. 3, pp. 143–152, 2002. View at Google Scholar · View at Scopus
  14. J. V. Lacey, M. E. Sherman, B. B. Rush et al., “Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 788–792, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. N. Bakkum-Gamez, J. Gonzalez-Bosquet, N. N. Laack, A. Mariani, and S. C. Dowdy, “Current issues in the management of endometrial cancer,” Mayo Clinic Proceedings, vol. 83, no. 1, pp. 97–112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. T. T. Nieminen, A. Gylling, W. M. Abdel-Rahman et al., “Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia,” Clinical Cancer Research, vol. 15, no. 18, pp. 5772–5783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Okuda, H. Nakamura, K. Yoshida et al., “Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor,” Cancer Science, vol. 94, no. 12, pp. 1034–1041, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. H. E. Tsai, G. S. Liu, M. L. Kung et al., “Downregulation of heptaoma-derived growth factor contributes to retarded lung metastasis via inhibition of epithelial-mesenchymal transition by systemic POMC gene delivery in melanoma,” Molecular Cancer Therapeutics, vol. 12, pp. 1016–1025, 2013. View at Google Scholar
  19. K. Yoshida, Y. Tomita, Y. Okuda et al., “Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma,” Annals of Surgical Oncology, vol. 13, no. 2, pp. 159–167, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Yamamoto, Y. Tomita, Y. Hoshida et al., “Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma,” Clinical Cancer Research, vol. 12, no. 1, pp. 117–122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Uyama, Y. Tomita, H. Nakamura et al., “Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer,” Clinical Cancer Research, vol. 12, no. 20, pp. 6043–6048, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Iwasaki, K. Nakagawa, H. Nakamura, Y. Takada, K. Matsui, and K. Kawahara, “Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer,” Oncology Reports, vol. 13, no. 6, pp. 1075–1080, 2005. View at Google Scholar · View at Scopus
  23. K. Chang, M. Tai, J. Lin et al., “Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors,” International Journal of Cancer, vol. 121, no. 5, pp. 1059–1065, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S. C. Chen, M. L. Kung, T. H. Hu et al., “Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial—mesenchymal transition,” The Journal of Pathology, vol. 228, pp. 158–169, 2012. View at Google Scholar
  25. K. A. Nicolaije, N. P. Ezendam, M. C. Vos et al., “Follow-up practice in endometrial cancer and the association with patient and hospital characteristics: a study from the population-based PROFILES registry,” Gynecologic Oncology, vol. 129, no. 2, pp. 324–331, 2013. View at Google Scholar